Mabxience Research S.l.
Clinical trials sponsored by Mabxience Research S.l., explained in plain language.
-
New biosimilar aims to match leading melanoma drug in major trial
Disease control Recruiting nowThis study tests whether MB11, a biosimilar (a nearly identical copy) of the cancer drug Opdivo, works as well and is as safe as the original drug. About 632 adults with advanced melanoma that has not been treated before will receive either MB11 or Opdivo. The goal is to see if t…
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 17, 2026 01:28 UTC
-
Could a cheaper keytruda copy work just as well for lung cancer?
Disease control Recruiting nowThis study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…
Phase: PHASE3 • Sponsor: mAbxience Research S.L. • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC